Evaluation of clinical outcomes after COMBO stent treatment in patients presenting with acute coronary syndrome.
BACKGROUND
Patients presenting with acute coronary syndrome (ACS) are at increased risk of complications after percutaneous coronary intervention with stent placement compared to patients with stable angina (SA) treated in an elective setting. The novel pro-healing COMBO stent is a bio-engineered drug eluting stent designed to promote vessel healing. Therefore, the stent may reduce this difference in clinical outcomes between elective and ACS-patients and prevent late stent thrombosis.


RESULTS
The European, prospective, multicenter, 1000 all-comers patient REMEDEE registry evaluates clinical outcomes after COMBO stent placement in ACS- and elective patients. The primary endpoint at 12 months is target lesion failure (TLF), a composite of cardiac death, target-vessel myocardial infarction and target lesion revascularization. A total of 49.9% (n = 498) of patients presented with acute coronary syndrome. TLF was 7.1% in ACS patients, definite and probable stent thrombosis was observed in 0.5% of ACS patients and in all within 9 days post stenting. We found no significant difference in TLF between ACS and non-ACS patients and a low overall rate of TLF.


CONCLUSIONS
The COMBO stent is a safe and efficient device for patients presenting with ACS. Low ST rate and only early stent thrombosis were observed. © 2017 Wiley Periodicals, Inc.
Academic Medical Center - University of Amsterdam, Amsterdam, The Netherlands.
Deborah N
DN
Kalkman
Academic Medical Center - University of Amsterdam, Amsterdam, The Netherlands.
Pier
http://orcid.org/0000-0002-5870-9923
P
Woudstra
Academic Medical Center - University of Amsterdam, Amsterdam, The Netherlands.
Huangling
H
Lu
Craigavon Cardiac Centre, Craigavon, United Kingdom.
Ian B A
IBA
Menown
Amphia Hospital Breda, Breda, The Netherlands.
Peter
P
den Heijer
Radboud University Medical Center, Nijmegen, The Netherlands.
Harry
H
Suryapranata
Hospital Álvaro Cunqueiro - Complejo Hospitalario Universitario, Vigo, Spain.
Andrés
A
Iñiguez
Tergooi Ziekenhuis, Blaricum, The Netherlands.
Karin E
KE
Arkenbout
Isala Klinieken, Zwolle, The Netherlands.
Arnoud W J
AWJ
Van't Hof
Institut National de Cardiochirurgie et de Cardiologie Interventionnelle, Luxembourg.
Philippe
P
Muller
Pauls Stradins Clinical University Hospital, Riga, Latvia.
Andrejs
A
Erglis
Academic Medical Center - University of Amsterdam, Amsterdam, The Netherlands.
Jan G
JG
Tijssen
Academic Medical Center - University of Amsterdam, Amsterdam, The Netherlands.
Marcel A M
MAM
Beijk
Academic Medical Center - University of Amsterdam, Amsterdam, The Netherlands.
Robbert J
RJ
de Winter
D054058:Acute Coronary Syndrome / Q000000981:diagnostic imaging / Q000401:mortality / Q000628:therapy*; D000368:Aged; D003328:Coronary Thrombosis / Q000209:etiology / Q000517:prevention & control; D004359:Drug Therapy, Combination; D054855:Drug-Eluting Stents; D005060:Europe; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000209:etiology / Q000517:prevention & control; D062645:Percutaneous Coronary Intervention / Q000009:adverse effects / Q000295:instrumentation* / Q000401:mortality; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage; D011446:Prospective Studies; D011474:Prosthesis Design; D012042:Registries; D012307:Risk Factors; D013997:Time Factors; D016896:Treatment Outcome
D010975:Platelet Aggregation Inhibitors
COMBO; PCI; acute coronary syndrome; clinical outcomes; endothelial progenitor cell; stent